文献速递帕金森病与运动障碍

LRRK2与GBA突变非显性携带者的临床及多巴胺转运体影像特征:PPMI横断面研究

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
PubMed 文献 · Lancet Neurol · 2019-10-31

基于PPMI队列33个中心的横断面分析,纳入208例LRRK2和184例GBA非显性携带者,比较其基线临床与DAT影像特征。两组运动及自主神经评分均显著高于健康对照,LRRK2携带者嗅觉减退更常见,GBA携带者DAT结合比值升高,提示突变携带者存在可早于DAT缺损的细微帕金森病征象。

要点

  • LRRK2与GBA非显性携带者MDS-UPDRS总分和自主神经功能评分显著高于健康对照。
  • 仅LRRK2携带者嗅觉减退比例显著高于健康对照。
  • GBA携带者尾状核、壳核和纹状体DAT结合比值显著高于健康对照,LRRK2无此差异。

核心结论

  • LRRK2和GBA非显性携带者较健康对照存在细微运动和非运动帕金森病征象,且可早于DAT缺损出现。

研究设计与样本

  • 基于PPMI前瞻性观察队列的横断面分析,纳入33个中心2014至2019年入组的208例LRRK2和184例GBA非显性携带者。
  • DAT缺损定义为壳核纹状体结合比值低于个体年龄预期值的65%。
  • 采用t检验、χ2检验和Fisher精确检验比较组间基线人口学特征,并用逆概率加权控制年龄和性别等混杂因素。

主要发现

  • 286例(73%)携带者有DAT影像结果,其中18例(11%)LRRK2和4例(3%)GBA携带者存在DAT缺损。

关键数值与推荐

  • DAT缺损判定标准为壳核纹状体结合比值低于个体年龄预期值的65%。
  • 日间嗜睡、焦虑、抑郁、冲动强迫障碍、血压、尿酸和REM睡眠行为障碍评分组间无差异。

临床怎么用

  • 对LRRK2和GBA非显性携带者应关注运动及自主神经症状,即使DAT影像尚未显示缺损。
  • LRRK2携带者嗅觉减退较常见,GBA携带者DAT结合比值可能升高,解读影像时需结合遗传背景。
  • 当前横断面数据尚不足以单独用于预测个体转化为帕金森病,需纵向随访确认。

局限性

  • 为横断面分析,无法确定临床征象与DAT缺损的时序关系及预测价值。
  • 仅73%携带者具备DAT影像结果,可能存在选择偏倚。
  • 随访数据尚缺,需纵向研究确认轨迹和帕金森病发生的预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Parkinson's Progression Markers Initiative (PPMI) is an ongoing observational, longitudinal cohort study of participants with Parkinson's disease, healthy controls, and carriers of the most common Parkinson's disease-related genetic mutations, which aims to define biomarkers of Parkinson's disease diagnosis and progression. All participants are assessed annually with a battery of motor and non-motor scales, 123-I Ioflupane dopamine transporter (DAT) imaging, and biological variables. We aimed to examine whether non-manifesting carriers of LRRK2 and GBA mutations have prodromal features of Parkinson's disease that correlate with reduced DAT binding. METHODS: This cross-sectional analysis is based on assessments done at enrolment in the subset of non-manifesting carriers of LRRK2 and GBA mutations enrolled into the PPMI study from 33 participating sites worldwide. The primary objective was to examine baseline clinical and DAT imaging characteristics in non-manifesting carriers with GBA and LRRK2 mutations compared with healthy controls. DAT deficit was defined as less than 65% of putamen striatal binding ratio expected for the individual's age. We used t tests, χ2 tests, and Fisher's exact tests to compare baseline demographics across groups. An inverse probability weighting method was applied to control for potential confounders such as age and sex. To account for multiple comparisons, we applied a family-wise error rate to each set of analyses. This study is registered with ClinicalTrials.gov, number NCT01141023. FINDINGS: Between Jan 1, 2014, and Jan 1, 2019, the study enrolled 208 LRRK2 (93% G2019S) and 184 GBA (96% N370S) non-manifesting carriers. Both groups were similar with respect to mean age, and about 60% were female. Of the 286 (73%) non-manifesting carriers that had DAT imaging results, 18 (11%) LRRK2 and four (3%) GBA non-manifesting carriers had a DAT deficit. Compared with healthy controls, both LRRK2 and GBA non-manifesting carriers had significantly increased mean scores on the Movement Disorders Society Unified Parkinson's Disease Rating Scale (total score 4·6 [SD 4·4] healthy controls vs 8·4 [7·3] LRRK2 vs 9·5 [9·2] GBA, p<0·0001 for both comparisons) and the Scale for Outcomes for PD - autonomic function (5·8 [3·7] vs 8·1 [5·9] and 8·4 [6·0], p<0·0001 for both comparisons). There was no difference in daytime sleepiness, anxiety, depression, impulsive-compulsive disorders, blood pressure, urate, and rapid eye movement (REM) behaviour disorder scores. Hyposmia was significantly more common only in LRRK2 non-manifesting carriers (69 [36%] of 194 healthy controls vs 114 [55%] of 208 LRRK2 non-manifesting carriers; p=0·0003). Finally, GBA but not LRRK2 non-manifesting carriers showed increased DAT striatal binding ratios compared with healthy controls in the caudate (healthy controls 2·98 [SD 0·63] vs GBA 3·26 [0·63]; p<0·0001), putamen (2·15 [0·56] vs 2·48 [0·52]; p<0·0001), and striatum (2·56 [0·57] vs 2·87 [0·55]; p<0·0001). INTERPRETATION: Our data show evidence of subtle motor and non-motor signs of Parkinson's disease in non-manifesting carriers compared with healthy controls that can precede DAT deficit. Longitudinal data will be essential to confirm these findings and define the trajectory and predictors for development of Parkinson's disease. FUNDING: Michael J Fox Foundation for Parkinson's Research.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Simuni T, Uribe L, Cho HR, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 2019. PMID: 31678032. doi:10.1016/S1474-4422(19)30319-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。